Circio logoCircio logo

  • About
      • About Circio
      • CEO Statement
      • Pipeline
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
  • circRNA
      • Circio AB
      • circVec platform
  • Clinical programs
      • KRAS program
      • Publications
  • Partnering
  • Investors
      • Rights issue 2024
      • Press releases
      • Events
      • Reports
      • Presentations
      • Prospectus
      • Debt
      • Share facts
      • Largest shareholders
      • Dividend policy
      • Analyst coverage
      • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Articles of Association
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Contact
  • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
  • Contacts
    • About
      • About Circio
      • CEO Statement
      • Our pipeline
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
    • circRNA
      • Circio AB
      • circVec platform
    • Clinical programs
      • KRAS program
      • Publications
    • Partnering
      • Partnering
    • Investors
      • Rights issue 2024
      • Press releases
      • Events
      • Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share and trading information
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
      • General Meetings
      • Articles of Association
      • Board of Directors
      • Nomination Committee
      • Committees
      • Management
      • Contact
    • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
    • Contacts
      • Offices
      • Investors & Media

    Targovax AS: Interim Report Q4 and YTD 2014

    December 31, 2014
    Press release - Non-regulatory

    See attached file for Interim Report Q4

    Documents

    • Interim Report Q4 and YTD 2014 (PDF)
    IR contact
    Dr Erik Digman Wiklund
    Dr Erik Digman Wiklund
    CEO
    erik.wiklund@circio.com
    (+47) 41 33 35 36
    Dr Lubor Gaal
    Dr Lubor Gaal
    CFO & Head of BD
    lubor.gaal@circio.com
    (+34) 683 343 811
    Circio logo

    Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

    • About
    • circRNA
    • Clinical programs
    • Partnering
    • Investors
    • Media
    • Contacts

    CONTACT

    Circio Holding ASA
    Email: contact@circio.com

    • Cookies
    • Privacy policy
    • STAY CONNECTED